| Literature DB >> 30559071 |
Defne A Amado1, Julianne M Rieders2, Fortunay Diatta1, Pilar Hernandez-Con1, Adina Singer1, Jordan T Mak1, Junxian Zhang1, Eric Lancaster1, Beverly L Davidson3, Alice S Chen-Plotkin4.
Abstract
Adeno-associated virus-mediated gene replacement is emerging as a safe and effective means of correcting single-gene mutations affecting the CNS. AAV-mediated progranulin gene (GRN) delivery has been proposed as a treatment for GRN-deficient frontotemporal dementia and neuronal ceroid lipofuscinosis, and recent studies using intraparenchymal AAV-Grn delivery to brain have shown moderate success in histopathologic and behavioral rescue in mouse models. Here, we used AAV9 to deliver GRN to the lateral ventricle to achieve widespread expression in the Grn null mouse brain. We found that, despite a global increase in progranulin, overexpression resulted in dramatic and selective hippocampal toxicity and degeneration affecting neurons and glia. Hippocampal degeneration was preceded by T cell infiltration and perivascular cuffing. GRN delivery with an ependymal-targeting AAV for selective secretion of progranulin into the cerebrospinal fluid similarly resulted in T cell infiltration, as well as ependymal hypertrophy. Interestingly, overexpression of GRN in wild-type animals also provoked T cell infiltration. These results call into question the safety of GRN overexpression in the CNS, with evidence for both a region-selective immune response and cellular proliferative response. Our results highlight the importance of careful consideration of target gene biology and cellular response to overexpression prior to progressing to the clinic.Entities:
Keywords: AAV; CNS gene therapy; brain gene therapy; frontotemporal dementia; neurodegeneration; neuronal ceroid lipofuscinosis; progranulin
Mesh:
Substances:
Year: 2018 PMID: 30559071 PMCID: PMC6369714 DOI: 10.1016/j.ymthe.2018.11.013
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454